

# UCLA

## UCLA Previously Published Works

### Title

Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry.

### Permalink

<https://escholarship.org/uc/item/4102f35x>

### Journal

JAMA, 322(17)

### ISSN

0098-7484

### Authors

Genetics of Glaucoma in People of African Descent (GGLAD) Consortium  
Hauser, Michael A  
Allingham, R Rand  
[et al.](#)

### Publication Date

2019-11-01

### DOI

10.1001/jama.2019.16161

Peer reviewed

# Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry

The Genetics of Glaucoma in People of African Descent (GGLAD) Consortium

**IMPORTANCE** Primary open-angle glaucoma presents with increased prevalence and a higher degree of clinical severity in populations of African ancestry compared with European or Asian ancestry. Despite this, individuals of African ancestry remain understudied in genomic research for blinding disorders.

**OBJECTIVES** To perform a genome-wide association study (GWAS) of African ancestry populations and evaluate potential mechanisms of pathogenesis for loci associated with primary open-angle glaucoma.

**DESIGN, SETTINGS, AND PARTICIPANTS** A 2-stage GWAS with a discovery data set of 2320 individuals with primary open-angle glaucoma and 2121 control individuals without primary open-angle glaucoma. The validation stage included an additional 6937 affected individuals and 14 917 unaffected individuals using multicenter clinic- and population-based participant recruitment approaches. Study participants were recruited from Ghana, Nigeria, South Africa, the United States, Tanzania, Britain, Cameroon, Saudi Arabia, Brazil, the Democratic Republic of the Congo, Morocco, Peru, and Mali from 2003 to 2018. Individuals with primary open-angle glaucoma had open iridocorneal angles and displayed glaucomatous optic neuropathy with visual field defects. Elevated intraocular pressure was not included in the case definition. Control individuals had no elevated intraocular pressure and no signs of glaucoma.

**EXPOSURES** Genetic variants associated with primary open-angle glaucoma.

**MAIN OUTCOMES AND MEASURES** Presence of primary open-angle glaucoma. Genome-wide significance was defined as  $P < 5 \times 10^{-8}$  in the discovery stage and in the meta-analysis of combined discovery and validation data.

**RESULTS** A total of 2320 individuals with primary open-angle glaucoma (mean [interquartile range] age, 64.6 [56-74] years; 1055 [45.5%] women) and 2121 individuals without primary open-angle glaucoma (mean [interquartile range] age, 63.4 [55-71] years; 1025 [48.3%] women) were included in the discovery GWAS. The GWAS discovery meta-analysis demonstrated association of variants at amyloid- $\beta$  A4 precursor protein-binding family B member 2 (*APBB2*; chromosome 4, rs59892895T>C) with primary open-angle glaucoma (odds ratio [OR], 1.32 [95% CI, 1.20-1.46];  $P = 2 \times 10^{-8}$ ). The association was validated in an analysis of an additional 6937 affected individuals and 14 917 unaffected individuals (OR, 1.15 [95% CI, 1.09-1.21];  $P < .001$ ). Each copy of the rs59892895\*C risk allele was associated with increased risk of primary open-angle glaucoma when all data were included in a meta-analysis (OR, 1.19 [95% CI, 1.14-1.25];  $P = 4 \times 10^{-13}$ ). The rs59892895\*C risk allele was present at appreciable frequency only in African ancestry populations. In contrast, the rs59892895\*C risk allele had a frequency of less than 0.1% in individuals of European or Asian ancestry.

**CONCLUSIONS AND RELEVANCE** In this genome-wide association study, variants at the *APBB2* locus demonstrated differential association with primary open-angle glaucoma by ancestry. If validated in additional populations this finding may have implications for risk assessment and therapeutic strategies.

JAMA. 2019;322(17):1682-1691. doi:10.1001/jama.2019.16161

← Related article page 1705

+ Supplemental content

**Author/Group Information:** The Genetics of Glaucoma in People of African Descent (GGLAD) Consortium members appear at the end of the article.

**Corresponding Author:** Michael A. Hauser, PhD, Duke University, 300 N Duke St, Room 50-101, Durham, NC 27901 (mike.hauser@duke.edu).

**P**rimarily open-angle glaucoma affects millions of people worldwide and is a leading cause of irreversible blindness.<sup>1,2</sup> Genome-wide association studies (GWASs) have identified more than 15 genetic loci associated with increased risk of primary open-angle glaucoma in populations with European or Asian ancestry,<sup>3,4</sup> and these results have been supported by analyses of glaucoma-associated quantitative traits, such as intraocular pressure (IOP) and vertical cup-to-disc ratio.<sup>5</sup> In contrast, although GWASs of individuals of African ancestry have been performed,<sup>6,7</sup> no genome-wide significant loci have been identified to date in this disproportionately affected population. Studies have shown that while individuals of European ancestry older than 40 years exhibit a disease prevalence of 1%, the prevalence is markedly higher in individuals with African ancestry older than 40 years (up to 6.8%).<sup>2,8,9</sup> Primary open-angle glaucoma also has earlier onset and is more severe in individuals of African ancestry.<sup>10-12</sup> A 2018 GWAS examining primary open-angle glaucoma in a multiethnic sample, the Genetic Epidemiology Research on Adult Health and Aging cohort, confirmed that there is a higher prevalence of primary open-angle glaucoma in individuals of African ancestry (16.1%) compared with individuals of East Asian (9.9%) and European (7.4%) ancestry.<sup>13</sup>

The objective of this study was to address this disparity in genomic science research by performing a GWAS of primary open-angle glaucoma via a multicenter research partnership to obtain biological insights into disease pathogenesis in individuals with African ancestry.

## Methods

### Study Populations

The study populations comprised 2 groups: the GWAS discovery stage followed by a validation stage. The validation stage included 2 separate meta-analyses. All participants were recruited using the same criteria in both stages. Individuals with primary open-angle glaucoma, control individuals without primary open-angle glaucoma, and eye and brain tissue donors (or family members of deceased donors) were enrolled after written informed consent was obtained from each participant, in full adherence to the Declaration of Helsinki. All relevant local and hospital institutional review boards approved the study. Participant ancestry was self-reported.

For the GWAS discovery stage, study participants of African ancestry were recruited from Ghana, Nigeria, South Africa, and Duke University (Durham, NC), where the same phenotype definition was applied to diagnose primary open-angle glaucoma.<sup>3,14,15</sup> Individuals with primary open-angle glaucoma were defined by the presence of glaucomatous optic neuropathy (defined as loss of neuroretinal rim with a vertical cup-to-disc ratio of >0.7 or an intereye asymmetry >0.2 and/or notching attributable to glaucoma) with compatible visual field loss, open angles on gonioscopy, and absence of secondary causes of glaucomatous optic neuropathy. Elevation of IOP was not a criterion in inclusion or

### Key Points

**Question** Are there differences in genetic risk factors for primary open-angle glaucoma based on ancestry?

**Findings** In this multistage, case-control, genome-wide association study that included 26 295 participants, the amyloid- $\beta$  A4 precursor protein-binding family B member 2 (*APBB2*) locus was significantly associated with primary open-angle glaucoma among individuals of African ancestry (odds ratio, 1.19 per copy of the risk allele for single-nucleotide polymorphism rs59892895T>C), but not of European or Asian ancestry.

**Meaning** This study identified a single-nucleotide polymorphism that demonstrated differential association with primary open-angle glaucoma by ancestry.

exclusion of patients. Patients who were unable to give informed consent or those with secondary glaucoma due to trauma, uveitis, neovascularization, exfoliation syndrome, or pigment dispersion were excluded. Control individuals were recruited in a hospital-based or population-based manner. Hospital-based control individuals were older than 40 years and were confirmed to have no sign of glaucoma or other major eye diseases. These participants had an IOP of less than 21 mm Hg with open angles at the time of recruitment, healthy optic nerves, normal visual fields, and no family history of glaucoma. Population-based control individuals were matched by hospital and ancestry and were healthy individuals older than 40 years. The participating institutions are listed in the eAppendix in the [Supplement](#). The sample collections from the discovery GWAS analysis were ascertained or reexamined between January 1, 2012, and December 31, 2017.

The study design and genotyping method for the 7 sample collections analyzed in the first validation meta-analysis have been previously described.<sup>6,7,13,16-18</sup> The study names of these collections are listed in the eAppendix in the [Supplement](#). The sample collections were ascertained or reexamined between January 1, 2003, and December 31, 2018.

The second validation meta-analysis included individuals with primary open-angle glaucoma and matched control individuals from Mali, Cameroon, Nigeria (Lagos, Kaduna, and Enugu), Brazil, Saudi Arabia, the Democratic Republic of the Congo, Morocco, and Peru. The participating hospital institutions are listed in the eAppendix in the [Supplement](#). These sample collections were ascertained or reexamined between January 1, 2015, and December 31, 2018.

### Genotyping and Quality Control Procedures

For the GWAS discovery stage, genome-wide genotyping was performed using the Illumina OmniExpress beadchip, which directly assessed more than 700 000 single-nucleotide polymorphism (SNP) markers across the human genome. This genotyping array has been successfully used in multiple genome-wide scans,<sup>19,20</sup> including scans for primary open-angle glaucoma and other forms of glaucoma.<sup>14,21</sup> Further details on GWAS genotyping and quality control procedures are included in the eAppendix in the [Supplement](#).

The first validation meta-analysis for amyloid- $\beta$  A4 precursor protein-binding family B member 2 (*APBB2*; Refseq [NM\\_004307](#)) rs59892895 was performed with genome-wide genotyping data from previously described matched primary open-angle glaucoma case-control data sets. The second validation meta-analysis for *APBB2* rs59892895 was performed with the Sequenom MassArray primer extension system, with the genotypes further verified with Applied Biosystems Taqman assays.

Fine-scale imputation analysis using the 1000 Genomes Project cosmopolitan reference panel was performed to increase the density of the discovery GWAS. The IMPUTE version 2 software package was used to perform the imputation.<sup>22</sup> Stringent quality control was applied on the imputed data by only including imputed genotypes with an information score of at least 0.95 and by only including SNPs with minor allele frequency of at least 1%. The imputation accuracy of *APBB2* rs59892895T>C was validated with direct genotyping using the MassArray (Sequenom) and Taqman (Applied Biosystems) systems (with >99% concordance).

#### Immunohistochemistry and Image Analysis of *APBB2* and $\beta$ -Amyloid in Donor Retina Tissues

*APBB2* was shown to increase  $\beta$ -amyloid flux through both the amyloidogenic and nonamyloidogenic pathways of amyloid precursor protein (APP) processing.<sup>23</sup> Donor eyes were selected from a tissue collection obtained from the Iowa Lions Eye Bank within 8 hours after death (eTable 1 in the [Supplement](#)). Retinal tissue sections from the donor eyes were assessed for *APBB2* and  $\beta$ -amyloid expression using immunohistochemistry and image analysis. Further details on the experimental methods are included in the eAppendix in the [Supplement](#).

#### Immunohistochemistry and Image Analysis of *APBB2* and $\beta$ -Amyloid in Primary Visual Cortex Tissues

All donor samples (eTable 2 in the [Supplement](#)) were obtained from the Duke Kathleen Price Bryan Brain Bank and Biorepository and were matched for age and Alzheimer disease severity stage using the Braak classification.<sup>24,25</sup> Sections from the primary visual cortex of the donor samples were assessed for *APBB2* and  $\beta$ -amyloid expression using immunohistochemistry and image analysis. Further details on the experimental methods are included in the eAppendix in the [Supplement](#).

#### Statistical Analysis

An analysis of the discovery GWAS and follow-up validation stages were prespecified. The evaluation of previously described loci and their consequences on primary open-angle glaucoma risk in the cohort of participants with African ancestry as well as studies exploring potential pathogenic mechanisms related to *APBB2* were undertaken in an exploratory, post hoc manner.

For the discovery GWAS analysis, the association between individual SNP genotypes and primary open-angle glaucoma risk was modeled additively for each copy of the

minor allele using logistic regression adjusted for the top 3 principal components of population stratification using PLINK, version 1.9 (details on principal component analysis are included in the eAppendix in the [Supplement](#)).<sup>26</sup> For imputed genotypes, the information content for allele dosage (range, 0-1; 1 indicates perfect information) were included into the association test model to account for and average across imputation uncertainty. The assumptions of this logistic regression model were that the effective sample size was sufficiently large to allow for  $\chi^2$ -distributed test statistics (eg, the Wald statistic for logistic regression) to be valid, for the observations to be independent of one another, and for only a low degree of collinearity to exist between the independent variables. The model assumptions were all met.

Genomic inflation ( $\lambda_{gc}$ ) in the GWAS discovery stage was estimated using the median regression test statistic. The genomic inflation factor is presented for each of the 4 GWAS discovery sites as well as for the GWAS discovery meta-analysis in eFigure 1 in the [Supplement](#). For the GWAS discovery analysis,  $P < 5 \times 10^{-8}$  (2-sided test) was considered statistically significant. In the validation stages, the association between *APBB2* rs59892895 and primary open-angle glaucoma risk was measured using logistic regression for an additive model. Because only 1 SNP (*APBB2* rs59892895) was tested in the first and second validation stages,  $P < .05$  (2-sided test) was considered statistically significant for each validation stage. Meta-analyses were conducted using the inverse-variance fixed-effects method (eAppendix in the [Supplement](#)).<sup>27</sup> Intercohort heterogeneity was assessed for the GWAS discovery and validation stages.

Previous case-control studies of primary open-angle glaucoma in individuals with European and Asian ancestry have robustly implicated at least 26 SNPs mapping to 15 distinct gene loci (*TMC01*, *FMNL2*, *CADM2*, *AFAP1*, *THSD7A*, *CAV1-CAV2*, *ANGPT1*, *CDKN2B-AS*, *ABCA1*, *LMX1B*, *PLCE1*, *TMT2C*, *SIX6*, *TCF12*, and *GAS7*), accompanied by validation in at least 2 independent studies.<sup>3,13,14,28-31</sup> The association between these 26 SNPs and primary open-angle glaucoma risk were tested using logistic regression in the collections from individuals with African ancestry, which included 5153 affected individuals and 10 014 unaffected individuals with available genotyping data. An inverse-variance, fixed-effects meta-analysis was conducted to summarize the estimates.

A case-only quantitative trait locus analysis was performed between *APBB2* rs59892895T>C and 2 clinical parameters: maximum IOP and vertical cup-to-disc ratio at the time of examination (using the mean ratio if available for both eyes). The association between *APBB2* rs59892895T>C and the clinical parameters was assessed using linear regression with sex and age as covariates. The fluorescence intensity data from the immunohistochemical analysis (eAppendix in the [Supplement](#)) of retina and primary visual cortex tissues were analyzed with regards to *APBB2* rs59892895T>C carrier status using a linear mixed model incorporating additional random effect terms for individual (for both retina and visual cortex data) and Braak stage (for visual cortex data only).

**Table. Summary of Case-Control Collections in a Study of the Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry**

Sample Collection <sup>a</sup>	rs59892895*C Present, %		Sample Size, No.	
	Individuals With Primary Open-Angle Glaucoma	Control Individuals Without Primary Open-Angle Glaucoma	Individuals With Primary Open-Angle Glaucoma	Control Individuals Without Primary Open-Angle Glaucoma
<b>GWAS Discovery</b>				
Ghana	26.9	23.3	833	896
Nigeria	30.4	22.6	554	348
South Africa	31.1	22.9	228	269
United States	26.1	21.7	705	608
Total			2320	2121
<b>First Validation</b>				
Women's Health Initiative	23.1	20.8	1720	6067
Kaiser Permanente GERA	23.3	18.4	300	2700
ADAGES	24.3	21.4	1890	2205
South Africa	13.0	14.4	297	147
Tanzania	30.1	28.3	366	329
United States	23.6	22.6	450	1350
South London	26.6	21.6	378	217
Total			5401	13 015
<b>Second Validation</b>				
Cameroon	31.3	29.0	56	57
Nigeria	28.6	26.2	231	61
Nigeria (Kaduna)	29.2	30.2	99	88
Nigeria (African Glaucoma Genetics Project)	32.6	31.0	131	71
Saudi Arabia	5.5	3.1	276	655
Brazil	8.8	4.5	399	460
The Democratic Republic of the Congo	37.7	33.9	124	120
Morocco	6.8	3.5	37	130
Peru	2.0	1.2	51	128
Mali	27.3	23.4	132	132
Total			1536	1902
All validation			6937	14 917
Total samples			9257	17 038

Abbreviations: ADAGES, African Descent and Glaucoma Evaluation Study; GERA, Genetic Epidemiology Research on Adult Health and Aging; GWAS, genome-wide association study.

<sup>a</sup> The study site (country) or name of the study that the sample collection was taken from. More information on the sample collections can be found in the eAppendix in the Supplement.


## Results

A total of 26 295 individuals were included in the study. The number of individuals with primary open-angle glaucoma and control individuals analyzed in the GWAS and validation stages are presented in the **Table** (quality control results and handling of population stratification can be found in the eAppendix and eFigures 1, 2, and 3 in the **Supplement**). The discovery meta-analysis identified a genome-wide significant association at 1 locus on chromosome 4, characterized by multiple SNP markers showing high pairwise linkage disequilibrium (**Figure 1**; summary statistics for the GWASs are publicly available per the data sharing statement). The association mapped to the *APBB2* rs59892895T>C locus (**Figure 2**), whereby the minor C allele was observed to be associated with increased risk of primary open-angle glau-

coma (per-allele odds ratio [OR], 1.32 [95% CI, 1.20-1.46];  $P = 2 \times 10^{-8}$ ).


The *APBB2* rs59892895 association was tested in the first validation meta-analysis comprising 7 independently ascertained sample collections from participants with African ancestry (**Table**). This first validation data set with prior genome-wide genotyping data available for 5401 individuals with primary open-angle glaucoma and 13 015 individuals without primary open-angle glaucoma had greater than 90% statistical power to validate an SNP with a minor allele frequency as low as 20% and an OR as low as 1.10 at a 2-sided  $P$  value less than .05.<sup>32</sup> The association at *APBB2* rs59892895 was validated, with the risk C allele associated with increased risk of primary open-angle glaucoma (OR, 1.13 [95% CI, 1.07-1.20];  $P < .001$ ; **Figure 3**). There was no significant heterogeneity across all sites analyzed ( $P$  value for heterogeneity = .15).

Figure 1. Discovery Analysis of 2320 Individuals With Primary Open-Angle Glaucoma and 2121 Age-Matched Control Individuals



Single-nucleotide polymorphisms (SNPs) were only considered if they were assessed across all 4 genome-wide association discovery study sites. A total of 6 734 161 SNPs are included in this figure. The blue horizontal line indicates a threshold for suggestive statistical significance commonly used in genome-wide association studies ( $P = 10^{-5}$ ) and the red horizontal line indicates the threshold for genome-wide significance ( $P = 5 \times 10^{-8}$ ). Multiple SNPs at the gene encoding for amyloid- $\beta$  A4 precursor protein-binding family B member 2 (*APBB2*) have a significant association with primary open-angle glaucoma disease risk.

Figure 2. Association at the Amyloid- $\beta$  A4 Precursor Protein-Binding Family B Member 2 (*APBB2*) Locus on Chromosome 4



The association between single-nucleotide polymorphisms (SNPs) and primary open-angle glaucoma were plotted by genomic position on chromosome 4 and degree of statistical significance. The horizontal line shows the threshold for genome-wide significance,  $P = 5 \times 10^{-8}$ . The dots indicate the extent of linkage disequilibrium (LD) between each tested SNP with rs59892895 (based on pairwise  $r^2$  values calculated from the discovery analysis). LD refers to the association between alleles of SNPs located close to one another on the same chromosome; SNPs in strong LD can serve as proxies for one another. Estimated


recombination rates were plotted in light blue to reflect the LD structure in individuals with African ancestry. The estimated recombination rate shows the average frequency in which recombination occurs at a particular location. The extent of LD drops with increasing recombination rate. The horizontal lines accompanied by arrows in the lower panel of the plot reflect the genes mapping to the given genomic locations. The arrows indicate the direction of transcription of the genes. The horizontal lines labeled *APBB2* and *RBM47* reflect 2 different gene transcripts of different lengths for both genes.

A second validation meta-analysis for this association was completed with an additional 1536 affected individuals and 1902 unaffected individuals with African ancestry (Table). A significant association between the rs59892895\*C allele and increased risk of primary open-angle glaucoma was observed (OR, 1.30 [95% CI, 1.12-1.51];  $P < .001$ ; Figure 3), with no significant heterogeneity across all 10 sites analyzed ( $P$  value for heterogeneity = .27). An overall meta-analysis of rs59892895\*C involving the 9257 individuals with primary open-angle glaucoma and 17 038 individuals without primary open-angle glaucoma from all cohorts showed consistent association with primary open-angle glaucoma risk (OR, 1.19 [95% CI, 1.14-1.25];  $P < .001$ ) (Figure 3). The rs59892895\*C allele was observed to not be significantly associated with IOP and vertical cup-to-disc

ratio ( $P = .62$ ) in an analysis of 6179 individuals of African ancestry with available data.

Only individuals of African ancestry or individuals with African ancestry admixture (eg, Brazil, Morocco, Peru, and Saudi Arabia; Table) were polymorphic at *APBB2* rs59892895—the rs59892895\*C risk allele was not present in European, South Asian, or East Asian individuals (eFigure 4 in the Supplement). The sources of data accessed to ascertain the frequency of rs59892895 in participants with other ancestries were from the 1000 Genomes Project browser<sup>33</sup> (eFigure 5 in the Supplement), the Genome Aggregation Database (gnOMAD; eTable 3 in the Supplement),<sup>34</sup> as well as previously published GWAS data sets of European<sup>3</sup> (eAppendix in the Supplement) and Asian individuals.<sup>15,35</sup> No SNP within the broad *APBB2* locus was

**Figure 3. Association Between Amyloid- $\beta$  A4 Precursor Protein-Binding Family B Member 2 (*APBB2*) rs59892895 and Primary Open-Angle Glaucoma Risk**



The oblong data markers represent odds ratios, with the height of the data markers being inversely proportional to the standard error of the odds ratio. The diamonds represent the odds ratios after the meta-analysis, with the width representing the 95% CIs. Collections from the United States were taken from

an African American population and the collection from South London was taken from a West African population. ADAGES indicates African Descent and Glaucoma Evaluation Study; AGGP, African Glaucoma Genetics Project; GWAS, genome-wide association study.

significantly associated with primary open-angle glaucoma in previously studied European or Asian ancestry case-control collections (eFigure 6 in the [Supplement](#)). *APBB2* rs59892895T>C was not observed to be in linkage disequilibrium (defined as pairwise  $r^2 > 0.8$ ) with other coding genetic variants or with potentially functional regulatory elements (eFigure 7 in the [Supplement](#)).

### Post Hoc Evaluation of Previously Described Loci and Their Consequences on Risk in the Cohorts

Analysis of 26 well-validated primary open-angle glaucoma SNPs from studies of individuals of European and Asian ancestry showed that for 23 of the 26 SNPs, the ORs in participants with African ancestry were smaller than in individuals with European ancestry. Heterogeneity tests showed 19 of the SNPs had *P* values for heterogeneity of less than .05 in support of a smaller OR in participants with African ancestry compared with European individuals (eTable 4 and eFigure 8 in the [Supplement](#)). Assessment of the relationship between IOP loci<sup>13,30</sup> and primary open-angle glaucoma risk showed a weak correlation between IOP and primary open-angle glaucoma risk in individuals with

African ancestry (eTable 5 and eFigure 9 in the [Supplement](#)). Assessment of the relationship between vertical cup-to-disc ratio loci<sup>36</sup> and primary open-angle glaucoma risk showed that all previously reported loci for vertical cup-to-disc ratio were not associated with primary open-angle glaucoma risk in participants with African ancestry (eTable 6 in the [Supplement](#)).

### Post Hoc Studies Exploring Potential Pathogenic Mechanisms Related to *APBB2*

All donor retina tissues were from individuals of African ancestry. For primary visual cortex tissues, carriers of the *APBB2* rs59892895\*C risk allele were of African ancestry, whereas 3 of the 4 individuals with the *APBB2* rs59892895\*TT homozygous baseline genotype were of European ancestry to match for the Braak stage of Alzheimer disease diagnosis (eTable 2 in the [Supplement](#)). Exploratory analyses using immunohistochemistry on donor retina and primary visual cortex tissues (eTable 1 and eTable 2 in the [Supplement](#)) suggested that participants carrying the rs59892895\*C risk allele had associated higher *APBB2* expression as well as associated increased staining

for  $\beta$ -amyloid compared with participants homozygous for the baseline rs59892895\*T nonrisk allele (eFigures 10, 11, and 12 in the Supplement).

## Discussion

This study of 26 295 individuals found a genetic variant in the *APBB2* gene that was associated with a higher risk of primary open-angle glaucoma. The genetic association between primary open-angle glaucoma and *APBB2* was observed only in individuals of African ancestry. The level of genetic diversity in participants of African ancestry was higher than in individuals of European or Asian ancestry, and the functional risk alleles in *APBB2* may not be present in these other populations. The increased risk associated with the *APBB2* allele appeared not to be mediated via increased IOP or optic nerve neuropathy associated with an increasing vertical cup-to-disc ratio, thus suggesting a new insight to primary open-angle glaucoma disease pathogenesis.

Because the odds ratio of the *APBB2* rs59892895\*C risk allele on primary open-angle glaucoma appeared to be larger in populations with African ancestry admixture, such as in Saudi Arabia, Brazil, Peru, and Morocco, this raised the possibility that estimates from these 4 populations could have been confounded by population stratification. However, principal component analysis of ancestry-informative markers from Brazil, Peru, and Morocco, which had sufficient DNA to allow assessment of these additional markers, revealed little evidence of population stratification between affected and unaffected individuals (eFigure 13 in the Supplement).

Because *APBB2* was shown to be involved in the amyloidogenic pathway of APP processing, an exploratory analysis of human retinal and primary visual cortex tissues suggested a potential relationship between the *APBB2* rs59892895\*C risk allele, increased *APBB2* expression, and associated increased  $\beta$ -amyloid plaque deposition. Primary open-angle glaucoma neurotoxicity may result from incomplete clearance of amyloid  $\beta$  and other neurotoxins from the interstitial space of the optic nerve.<sup>37</sup> However, there has been no conclusive evi-

dence that these pathways contribute to primary open-angle glaucoma in humans.

The present analysis suggests that the majority of open-angle glaucoma genetic loci described in individuals of European or Asian ancestry have a much more modest effect in individuals of African ancestry. Also, in contrast to studies of European individuals, the present data on individuals of African ancestry showed a much weaker correlation between genetic factors contributing to increased IOP and primary open-angle glaucoma risk. It is possible that these differences in genetic architecture are, at least in part, responsible for the increased prevalence and severity of primary open-angle glaucoma in African ancestry populations.

## Limitations

This study has several limitations. First, despite the moderately large sample size of participants of African ancestry, there was only sufficient statistical power to detect associations with common genetic variants. Second, although all study sites used well-established clinical protocols to diagnose primary open-angle glaucoma, the heterogeneity of the primary open-angle glaucoma phenotype may have limited the ability to detect some genetic associations by biasing the effect estimates toward the null. Third, while the association observed between *APBB2* rs59892895 and primary open-angle glaucoma risk was statistically significant, the causal mechanisms of association have yet to be elucidated. Fourth, because the observations from human retinal and visual cortex tissues in this report are based on limited sample sizes, they are interpreted here as exploratory and hypothesis generating, and would require further validation through future research.

## Conclusions

In this GWAS, variants at the *APBB2* locus demonstrated differential association with primary open-angle glaucoma by ancestry. If validated in additional populations this may have implications for risk assessment and therapeutic strategies.

### ARTICLE INFORMATION

**Accepted for Publication:** September 13, 2019.

**The Genetics of Glaucoma in People of African Descent (GGLAD) Consortium:** Michael A. Hauser, PhD; R. Rand Allingham, MD; Tin Aung, MD, PhD; Carly J. Van Der Heide, MD; Kent D. Taylor, PhD; Jerome I. Rotter, MD; Shih-Hsiu J. Wang, MD, PhD; Pieter W. M. Bonnemaier, MD; Susan E. Williams, MD; Sadiq M. Abdullahi, MD; Khaled K. Abu-Amero, PhD; Michael G. Anderson, PhD; Stephen Akafo, MD; Mahmoud B. Alhassan, MD; Ifeoma Asimadu, MD; Radha Ayyagari, PhD; Saydou Bakayoko, MD; Prisca Biangoup Nyamsi, MD; Donald W. Bowden, PhD; William C. Bromley, MD; Donald L. Budenz, MD; Trevor R. Carmichael, MD, PhD; Pratap Challa, MD; Yii-Der Ida Chen, PhD; Chimdi M. Chuka-Okosa, MD; Jessica N. Cooke Bailey, PhD; Vital Paulino Costa, MD; Dianne A. Cruz, MS; Harvey DuBiner, MD; John F. Ervin, BA; Robert M. Feldman, MD; Miles Flamme-Wiese, BSE; Douglas E. Gaasterland,

MD; Sarah J. Garnai, BS; Christopher A. Girkin, MD; Nouhoum Guirou, MD; Xiuqing Guo, PhD; Jonathan L. Haines, PhD; Christopher J. Hammond, MD; Leon Herndon, MD; Thomas J. Hoffmann, PhD; Christine M. Hulette, MD; Abba Hydar, MD; Robert P. Igo Jr, PhD; Eric Jorgenson, PhD; Joyce Kabwe, MD; Ngoy Janvier Kilangalanga, MD; Nkiru Kizor-Akaraiwe, MD; Rachel W. Kuchtey, MD, PhD; Hasnaa Lamari, MD; Zheng Li, MD, PhD; Jeffrey M. Liebmann, MD; Yutao Liu, PhD; Ruth J.F. Loos, PhD; Monica B. Melo, PhD; Sayoko E. Moroi, MD, PhD; Joseph M. Msosa, MD; Robert F. Mullins, PhD; Girish Nadkarni, MD; Abdoulaye Napo, MD; Maggie C. Y. Ng, PhD; Hugo Freire Nunes, PhD; Ebenezer Obeng-Nyarkoh, MA; Anthony Okeke, MD; Suhanya Okeke, MD; Olusegun Olaniyi, MD; Olusola Olawoye, MD; Mariana Borges Oliveira, MD; Louise R. Pasquale, MD; Rodolfo A. Perez-Grossmann, MD; Margaret A. Pericak-Vance, PhD; Xue Qin, PhD; Michele Ramsay, PhD; Serge Resnikoff, MD, PhD; Julia E. Richards,

PhD; Rui Barroso Schimiti, MD; Kar Seng Sim, MS; William E. Sponsel, MD; Paulo Vinicius Svidnicki, PhD; Alberta A. H. J. Thiadens, MD, PhD; Nkechinyere J. Uche, MD; Cornelia M. van Duijn, PhD; José Paulo Cabral de Vasconcellos, MD, PhD; Janey L. Wiggs, MD, PhD; Linda M. Zangwill, PhD; Neil Risch, PhD; Dan Milea, MD, PhD; Adayinka Ashaye, MD; Caroline C. W. Klaver, MD, PhD; Robert N. Weinreb, MD; Allison E. Ashley Koch, PhD; John H. Fingert, MD, PhD; Chiea Chuen Khor, MD, PhD.

**Affiliations of The Genetics of Glaucoma in People of African Descent (GGLAD) Consortium:** Department of Medicine, Duke University, Durham, North Carolina (Hauser, Ashley Koch); Department of Ophthalmology, Duke University, Durham, North Carolina (Hauser, Allingham, Challa, Herndon); Singapore Eye Research Institute, Singapore (Hauser, Allingham, Aung, Milea, Khor); Duke-NUS Medical School, Singapore (Hauser, Allingham, Aung, Milea); Singapore National Eye Center,



Singapore (Aung, Milea); Department of Ophthalmology, Young Loo Lin School of Medicine, Singapore (Aung); Carver College of Medicine, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City (Van Der Heide, Anderson, Flamme-Wiese, Mullins, Fingert); The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California (Taylor, Rotter, Chen, Guo); Department of Pediatrics, Harbor-University of California, Los Angeles Medical Center, Torrance (Taylor, Chen); Department of Pathology, Duke University, Durham, North Carolina (Wang, Hulette); Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands (Bonnemajjer, Thiadens, van Duijn, Klaver); Rotterdam Eye Hospital, Rotterdam, the Netherlands (Bonnemajjer); Department of Ophthalmology, Erasmus MC, Rotterdam, the Netherlands (Bonnemajjer, Thiadens, Klaver); Division of Ophthalmology, Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa (Williams, Carmichael); National Eye Centre, Kaduna, Nigeria (Abdullahi, Alhassan, Olaniyi); Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia (Abu-Amero); Unit of Ophthalmology, Department of Surgery, University of Ghana Medical School, Accra, Ghana (Akafo); Department of Ophthalmology, ESUT Teaching Hospital Parklane, Enugu, Nigeria (Asimadu, Kizor-Akaraiwe, S. Okeke); Shiley Eye Institute, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla (Ayyagari, Zangwill, Weinreb); Institut d'Ophtalmologie Tropicale de l'Afrique, Bamako, Mali (Bakayoko, Guirou, Napo); Université des Sciences des Techniques et des Technologies de Bamako, Bamako, Mali (Bakayoko, Guirou, Napo); Service Spécialisé d'ophtalmologie, Hôpital Militaire de Région No1 de Yaoundé, Yaoundé, Cameroun (Nyamsi); Center for Diabetes Research, Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina (Bowden, Ng); Center for Human Genetics, Bar Harbor, Maine (Bromley, Obeng-Nyarkoh); Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Budenz); University of Nigeria Teaching Hospital, Ituku Ozalla, Enugu, Nigeria (Chuka-Okosa, Uche); Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio (Cooke Bailey, Haines, Igo Jr); Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio (Cooke Bailey, Haines); Department of Ophthalmology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil (Costa, de Vasconcellos); Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina (Cruz); Clayton Eye Care Center Management Inc, Marrow, Georgia (DuBiner); Kathleen Price Bryan Brain Bank and Biorepository, Department of Neurology, Duke University, Durham, North Carolina (Ervin); McGovern Medical School, Ruiz Department of Ophthalmology & Visual Science, The University of Texas Health Science Center at Houston, Houston, (Feldman); The Emmes Corporation, Rockville, Maryland (Gaasterland); Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor (Garnai, Moroi, Richards); Department of Ophthalmology and Visual Sciences,

University of Alabama at Birmingham (Girkin); Section of Academic Ophthalmology, School of Life Course Sciences, FoLSM, King's College London, London, United Kingdom (Hammond); Department of Epidemiology and Biostatistics, University of California at San Francisco (Hoffmann, Risch); Institute for Human Genetics, University of California at San Francisco (Hoffmann, Risch); Sheikh Zayed Regional Eye Care Centre, Kanifing, The Gambia (Hydara); Division of Research, Kaiser Permanente Northern California, Oakland (Jorgenson, Risch); Department of Ophthalmology, St Joseph Hospital, Kinshasa, Limete, Democratic Republic of the Congo (Kabwe, Kilangalanga); The Eye Specialists Hospital, Enugu, Nigeria (Kizor-Akaraiwe, S. Okeke, Uche); Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee (Kuchtey); Clinique Spécialisée en Ophtalmologie Mohammedia, Mohammedia, Morocco (Lamari); Genome Institute of Singapore, Singapore (Li, Sim, Khor); Bernard and Shirlee Brown Glaucoma Research Laboratory, Harkness Eye Institute, Columbia University Medical Center, New York, New York (Liebmann); Cellular Biology and Anatomy, Augusta University, Augusta, Georgia (Liu); James & Jean Culver Vision Discovery Institute, Augusta University, Augusta, Georgia (Liu); Center for Biotechnology & Genomic Medicine, Augusta University, Augusta, Georgia (Liu); The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Loos, Nadkarni); The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York (Loos); Center for Molecular Biology and Genetic Engineering, University of Campinas, Campinas, Brazil (Melo, Nunes, Oliveira, Svidnicki); Lions Sight-First Eye Hospital, Kamuzu Central Hospital, Lilongwe, Malawi (Msosa); Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Nadkarni); Nigerian Navy Reference Hospital, Ojo, Lagos, Nigeria (A. Okeke); Department of Ophthalmology, University of Ibadan, Ibadan, Nigeria (Olawoye, Ashaye); Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York (Pasquale); Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts (Pasquale); Instituto de Glaucoma y Catarata, Lima, Peru (Perez-Grossmann); John P Hussen Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida (Pericak-Vance); Duke Molecular Physiology Institute, Duke University, Durham, North Carolina (Qin); Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (Ramsay); Brien Holden Vision Institute, Sydney, Australia (Resnikoff); School of Optometry and Vision Science, University of New South Wales, Sydney, Australia (Resnikoff); Department of Epidemiology, University of Michigan, Ann Arbor (Richards); Hoftalon Hospital, Londrina, Brazil (Schimiti); San Antonio Eye Health, San Antonio, Texas (Sponsel); Eyes of Africa, Child Legacy International (CLI) Hospital, Msundwe, Malawi (Sponsel); Nuffield Department of Public Health, University of Oxford, Oxford, United Kingdom (van Duijn); Harvard University Medical School, Boston, Massachusetts (Wiggs); Massachusetts Eye and Ear Hospital, Boston (Wiggs); Department of

Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands (Klaver).

**Author Contributions:** Drs Hauser and Khor had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Hauser, Allingham, Aung, Van Der Heide, Taylor, Rotter, Wang, Bonnemajjer, Williams, Risch, Milea, Ashaye, Klaver, Weinreb, Ashley Koch, Fingert, and Khor contributed to the work equally.

**Concept and design:** Hauser, Allingham, Aung, Rotter, Wang, Abu-Amero, Asimadu, Bromley, Li, Msosa, S. Okeke, Richards, Sponsel, Zangwill, Weinreb, Ashaye, Fingert, Khor.

**Acquisition, analysis, or interpretation of data:** Hauser, Allingham, Aung, van der Heide, Taylor, Rotter, Wang, Bonnemajjer, Williams, Abdullahi, Abu-Amero, Anderson, Akafo, Alhassan, Asimadu, Ayyagari, Bakayoko, Nyamsi, Bowden, Bromley, Budenz, Carmichael, Challa, Chen, Chuka-Okosa, Cooke Bailey, Costa, Cruz, DuBiner, Ervin, Feldman, Flamme-Wiese, Gaasterland, Garnai, Girkin, Guirou, Guo, Haines, Hammond, Herndon, Hulette, Hydara, Igo, Jorgenson, Kabwe, Kilangalanga, Kizor-Akaraiwe, Kuchtey, Lamari, Li, Liebmann, Liu, Loos, Melo, Moroi, Mullins, Nadkarni, Napo, Ng, Nunes, Obeng-Nyarkoh, C. Okeke, S. Okeke, Olaniyi, Olawoye, Oliveira, Pasquale, Perez-Grossmann, Pericak-Vance, Qin, Ramsay, Resnikoff, Richards, Schimiti, Sim, Svidnicki, Thiadens, Uche, van Duijn, Cabral de Vasconcellos, Wiggs, Zangwill, Risch, Milea, Ashaye, Klaver, Weinreb, Ashley Koch, Fingert, Khor.

**Drafting of the manuscript:** Hauser, Allingham, Aung, van der Heide, Wang, Anderson, Bromley, Cooke Bailey, Costa, Ervin, Gaasterland, Hulette, Lamari, Li, Melo, Obeng-Nyarkoh, Oliveira, Pasquale, Svidnicki, Ashley Koch, Khor.

**Critical revision of the manuscript for important intellectual content:** Aung, van der Heide, Taylor, Rotter, Wang, Bonnemajjer, Williams, Abdullahi, Abu-Amero, Anderson, Akafo, Alhassan, Asimadu, Ayyagari, Bakayoko, Nyamsi, Bowden, Budenz, Carmichael, Challa, Chen, Chuka-Okosa, Costa, Cruz, DuBiner, Feldman, Flamme-Wiese, Gaasterland, Garnai, Girkin, Guirou, Guo, Haines, Hammond, Herndon, Hydara, Igo, Jorgenson, Kabwe, Kilangalanga, Kizor-Akaraiwe, Kuchtey, Liebmann, Liu, Loos, Moroi, Msosa, Mullins, Nadkarni, Napo, Ng, Nunes, C. Okeke, S. Okeke, Olaniyi, Olawoye, Perez-Grossmann, Pericak-Vance, Qin, Ramsay, Resnikoff, Richards, Schimiti, Sim, Sponsel, Svidnicki, Thiadens, Uche, van Duijn, Cabral de Vasconcellos, Wiggs, Zangwill, Risch, Milea, Ashaye, Klaver, Weinreb, Ashley Koch, Fingert, Khor.

**Statistical analysis:** Taylor, Bonnemajjer, Cooke Bailey, Guo, Hammond, Igo, Jorgenson, Li, Qin, Sim, van Duijn, Wiggs, Risch, Klaver, Ashley Koch, Fingert, Khor.

**Obtained funding:** Hauser, Allingham, Aung, Rotter, Anderson, Girkin, Haines, Hammond, Jorgenson, Liebmann, Liu, Loos, Pericak-Vance, Richards, Zangwill, Klaver, Weinreb, Fingert, Khor.

**Administrative, technical, or material support:** Hauser, Allingham, Aung, Rotter, Wang, Abdullahi, Asimadu, Ayyagari, Bakayoko, Nyamsi, Bowden, Bromley, Carmichael, Challa, Chen, Cruz, DuBiner, Ervin, Feldman, Flamme-Wiese, Girkin, Guirou, Haines, Hulette, Hydara, Kabwe, Kilangalanga, Kizor-Akaraiwe, Kuchtey, Lamari, Li, Liebmann, Liu, Melo, Moroi, Mullins, Nadkarni, Napo, Ng, Obeng-Nyarkoh, S. Okeke, Olawoye,

Perez-Grossmann, Richards, Schimiti, Sponsel, Svidnicki, Thiadens, Uche, Cabral de Vasconcellos, Zangwill, Milea, Ashaye, Weinreb.

**Supervision:** Hauser, Allingham, Rotter, Anderson, Ayyagari, Budenz, Chen, Costa, Girkin, Hammond, Hulette, Jorgenson, Liebmann, Loos, Msosa, Nunes, Pasquale, Richards, Klaver, Fingert, Khor.

**Other - Part of South African group that contributed a cohort to the study:** Ramsay.

**Other - recruited subjects:** Moroi.

**Other - collection of samples:** Nyamsi, Resnikoff.

**Other - part of a South African group that contributed a cohort to the study:** Williams.

**Conflict of Interest Disclosures:** Dr Rotter reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Williams reported receiving grants from the Carnegie Corporation Transformation project at the University of the Witwatersrand and grants and personal fees from the Carnegie Corporation Clinician Scientist Fellowship during the conduct of the study. Dr Anderson reported receiving grants from the National Eye Institute (NEI)/NIH and the US Department of Veterans Affairs Rehabilitation Research and Development Service during the conduct of the study. Dr Nyamsi reported receiving nonfinancial support from the Singapore Eye Research Institute during the conduct of the study. Dr Bromley reported collaboration with the University of Michigan W.K. Kellogg Eye Center. Dr Chen reported receiving grants from NIH during the conduct of the study. Dr Cooke Bailey reported being supported by the Clinical and Translational Science Collaborative of Cleveland (KL2TRO002547) from the National Center for Advancing Translational Sciences/NIH and the NIH Roadmap for Medical Research during the conduct of the study. Dr Flamme-Wiese reported receiving grants from NIH (P30EY025580) during the conduct of the study. Dr Haines reported receiving grants from NIH during the conduct of the study. Dr Hammond reported receiving grants from the International Glaucoma Association during the conduct of the study. Dr Kizor-Akariwe reported receiving nonfinancial support from Singapore Eye Research Institute/Singapore National Eye Center outside the submitted work. Dr Liebmann reported receiving grants from NEI/NIH during the conduct of the study. Dr Melo reported receiving grants from São Paulo Research Foundation during the conduct of the study. Dr Nadkarni reported receiving personal fees from Renalytix AI BioVie outside the submitted work. Dr Napo reported receiving personal fees from IOTA during the conduct of the study. Dr Pasquale reported receiving personal fees from Bausch & Lomb and Verily outside the submitted work. Dr Resnikoff reported receiving personal fees from Laboratoires Thea outside the submitted work. Dr Richards reported receiving grants from NIH and Research to Prevent Blindness during the conduct of the study and royalties from Elsevier outside the submitted work. Dr Cabral de Vasconcellos reported receiving grants from São Paulo Research Foundation during the conduct of the study. Dr Wiggs reported receiving grants from NEI during the conduct of the study and consulting for Aerie Pharmaceuticals outside the submitted work. Dr Zangwill reported receiving grants from NEI during the conduct of the study and grants and nonfinancial support from Heidelberg Engineering, Topcon Inc, Carl Zeiss Meditec, and Optovue outside the submitted work.

Dr Weinreb reported receiving personal fees from Aerie Pharmaceuticals, Allergan, Eyenovia, and Implantdata; nonfinancial support from Heidelberg Engineering and Carl Zeiss Meditec; and grants from Genentech, Konan, Optovue, Topcon, Optos, Cetervue, and Bausch & Lomb outside the submitted work. No other disclosures were reported.

**Funding/Support:** Funding for the discovery genome-wide association study was provided by Duke-National University of Singapore. Additional support was provided by the National Eye Institute/National Institutes of Health (grant numbers EY023704, P30EY022589, EY110008, EY019869, EY021818, EY023242, EY028671, EY015473, EY022305, P30 EY014104, and EY023512) and the National Institutes of Health (grant numbers R01 DK087914, R01 DK066358, R01 DK053591, U01 DK105556, R01 HL56266, R01 DK070941, DRC DK063491, CTSI UL1T001881, R01DK110113, R01DK101855, R01DK107786, U01HG007417, and 1U54-HG009826); the Combined Ophthalmic Research Rotterdam, Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Landelijke Stichting voor Blinden en Slechtzienden, Stichting Beheer Het Schild, Prof Dr Henkes Stichting, Rotterdamse Stichting Blindenbelangen, Stichting Glaucomafonds, The Andrea and Charles Bronfman Philanthropies, the National Research Foundation of Singapore (NRF-NRF12018-01), the São Paulo Research Foundation (FAPESP 10/18353-9, FAPESP 02/11575-0), the EyeSight Foundation of Alabama (Dr Girkin), Research to Prevent Blindness (Dr Girkin), the Carnegie Corporation Transformation project at the University of the Witwatersrand grant, the BrightFocus Foundation, the Glaucoma Foundation, the Glaucoma Research Foundation, the International Glaucoma Foundation, and Leonard and Marlene Hadley. Some samples used in this study were provided by the Kathleen Price Bryan Brain Bank of the Joseph and Kathleen Bryan Alzheimer's Disease Research Center at Duke University (NIA P30 AGO28377).

**Role of the Funder/Sponsor:** None of the external funders or sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The contents do not represent the views of the US Department of Veterans Affairs or the US government.

**Data Sharing Statement:** The summary statistics for the GWAS discovery data set are available at [https://s3-ap-southeast-1.amazonaws.com/gis-hg4-poag/poag\\_africa\\_4\\_collection\\_logistic.meta.sorted\\_N4.tsv.zip](https://s3-ap-southeast-1.amazonaws.com/gis-hg4-poag/poag_africa_4_collection_logistic.meta.sorted_N4.tsv.zip).

**Additional Contributions:** We thank Christine Ntim-Amposah, MD (deceased), for contributing to participant ascertainment at the Ophthalmology unit of the Department of Surgery, University of Ghana Medical School, Ghana.

## REFERENCES

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol*. 2006;90(3):262-267. doi:10.1136/bjo.2005.081224

2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013

3. Bailey JN, Loomis SJ, Kang JH, et al; ANZRAG Consortium. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. *Nat Genet*. 2016;48(2):189-194. doi:10.1038/ng.3482

4. Shiga Y, Akiyama M, Nishiguchi KM, et al; Japan Glaucoma Society Omics Group (JGS-OG); NEIGHBORHOOD Consortium. Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. *Hum Mol Genet*. 2018;27(8):1486-1496. doi:10.1093/hmg/ddy053

5. Gharahkhani P, Burdon KP, Cooke Bailey JN, et al; NEIGHBORHOOD consortium. Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma. *Sci Rep*. 2018;8(1):3124. doi:10.1038/s41598-018-20435-9

6. Taylor KD, Guo X, Zangwill LM, et al; African Descent and Glaucoma Evaluation Study III Genomics Study Group. Genetic architecture of primary open-angle glaucoma in individuals of African descent: the African descent and glaucoma evaluation study III. *Ophthalmology*. 2019;126(1):38-48. doi:10.1016/j.ophtha.2018.10.031

7. Bonnemaijer PWM, Iglesias AI, Nadkarni GN, et al; GIGA Study Group; Eyes of Africa Genetics Consortium; NEIGHBORHOOD Consortium. Genome-wide association study of primary open-angle glaucoma in continental and admixed African populations. *Hum Genet*. 2018;137(10):847-862. doi:10.1007/s00439-018-1943-7

8. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. *JAMA*. 1991;266(3):369-374. doi:10.1001/jama.1991.03470030069026

9. Budenz DL, Barton K, Whiteside-de Vos J, et al; Tema Eye Survey Study Group. Prevalence of glaucoma in an urban West African population: the Tema Eye Survey. *JAMA Ophthalmol*. 2013;131(5):651-658. doi:10.1001/jamaophthalmol.2013.1686

10. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. *Ophthalmology*. 2002;109(6):1047-1051. doi:10.1016/S0161-6420(02)01040-0

11. Leske MC, Connell AM, Wu SY, et al; The Barbados Eye Studies Group. Incidence of open-angle glaucoma: the Barbados Eye Studies. *Arch Ophthalmol*. 2001;119(1):89-95.

12. Bengtsson BO. Incidence of manifest glaucoma. *Br J Ophthalmol*. 1989;73(7):483-487. doi:10.1136/bjo.73.7.483

13. Choquet H, Paylakhi S, Kneeland SC, et al. A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. *Nat Commun*. 2018;9(1):2278. doi:10.1038/s41467-018-04555-4

14. Gharahkhani P, Burdon KP, Fogarty R, et al; Wellcome Trust Case Control Consortium 2, NEIGHBORHOOD consortium. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary

- open-angle glaucoma. *Nat Genet.* 2014;46(10):1120-1125. doi:10.1038/ng.3079
15. Li Z, Allingham RR, Nakano M, et al; ICAARE-Glaucoma Consortium; NEIGHBORHOOD Consortium. A common variant near TGFBR3 is associated with primary open angle glaucoma. *Hum Mol Genet.* 2015;24(13):3880-3892. doi:10.1093/hmg/ddv128
16. Choquet H, Thai KK, Yin J, et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. *Nat Commun.* 2017;8(1):2108. doi:10.1038/s41467-017-01913-6
17. Hoffmann TJ, Tang H, Thornton TA, et al. Genome-wide association and admixture analysis of glaucoma in the Women's Health Initiative. *Hum Mol Genet.* 2014;23(24):6634-6643. doi:10.1093/hmg/ddu364
18. Zangwill LM, Ayyagari R, Liebmann JM, et al; African Descent and Glaucoma Evaluation Study III Genomics Study Group. The African Descent and Glaucoma Evaluation Study (ADAGES) III: contribution of genotype to glaucoma phenotype in African Americans: study design and baseline data. *Ophthalmology.* 2019;126(1):156-170. doi:10.1016/j.ophtha.2017.11.031
19. Christophersen IE, Rienstra M, Roselli C, et al; METASTROKE Consortium of the ISGC; Neurology Working Group of the CHARGE Consortium; AFGen Consortium. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. *Nat Genet.* 2017;49(6):946-952. doi:10.1038/ng.3843
20. McGinnis R, Steinhorsdottir V, Williams NO, et al; FINNPEC Consortium; GOPEC Consortium. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. *Nat Genet.* 2017;49(8):1255-1260. doi:10.1038/ng.3895
21. Aung T, Ozaki M, Lee MC, et al. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. *Nat Genet.* 2017;49(7):993-1004. doi:10.1038/ng.3875
22. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet.* 2012;44(8):955-959. doi:10.1038/ng.2354
23. Chang Y, Tesco G, Jeong WJ, et al. Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. *J Biol Chem.* 2003;278(51):51100-51107. doi:10.1074/jbc.M309561200
24. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 1991;82(4):239-259. doi:10.1007/BF00308809
25. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement.* 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007
26. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007;81(3):559-575. doi:10.1086/519795
27. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet.* 2016;48(2):134-143. doi:10.1038/ng.3448
28. Chen Y, Lin Y, Vithana EN, et al. Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma. *Nat Genet.* 2014;46(10):1115-1119. doi:10.1038/ng.3078
29. Hysi PG, Cheng CY, Springelkamp H, et al; BMES GWAS Group; NEIGHBORHOOD Consortium; Wellcome Trust Case Control Consortium 2. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. *Nat Genet.* 2014;46(10):1126-1130. doi:10.1038/ng.3087
30. Khawaja AP, Cooke Bailey JN, Wareham NJ, et al; UK Biobank Eye and Vision Consortium; NEIGHBORHOOD Consortium. Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nat Genet.* 2018;50(6):778-782. doi:10.1038/s41588-018-0126-8
31. MacGregor S, Ong JS, An J, et al. Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. *Nat Genet.* 2018;50(8):1067-1071. doi:10.1038/s41588-018-0176-y
32. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics.* 2003;19(1):149-150. doi:10.1093/bioinformatics/19.1.149
33. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature.* 2015;526(7571):68-74. doi:10.1038/nature15393
34. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature.* 2016;536(7616):285-291. doi:10.1038/nature19057
35. Khor CC, Do T, Jia H, et al. Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. *Nat Genet.* 2016;48(5):556-562. doi:10.1038/ng.3540
36. Springelkamp H, Höhn R, Mishra A, et al; Blue Mountains Eye Study—GWAS group; NEIGHBORHOOD Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2). Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. *Nat Commun.* 2014;5:4883. doi:10.1038/ncomms5883
37. Wostyn P, De Groot V, Van Dam D, Audenaert K, Killer HE, De Deyn PP. Glaucoma considered as an imbalance between production and clearance of neurotoxins. *Invest Ophthalmol Vis Sci.* 2014;55(8):5351-5352. doi:10.1167/iovs.14-15041